Precision Biosciences Inc (DTIL)

$4.45 -0.19 (-4.09%)
Market Cap 51.45M
Revenue (ttm) 68.70M
Net Income (ttm) 7.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.44%
Debt to Equity Ratio 0.45
Volume 137,900
Avg Vol 271,576
Day's Range N/A - N/A
Shares Out 11.09M
Stochastic %K 43%
Beta 1.43
Analysts Strong Sell
Price Target $34.50

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 314 5512
Fax: 480 393 5553
Address:
302 East Pettigrew St., Suite A-100, Durham, United States
Impatient_Investor
Impatient_Investor Jul. 16 at 6:01 AM
$DTIL DTIL's partner shareholding below. See the institutional shareholding. Retailers always chase garbage stocks because they are being manipulated and trapped by paid pumpers like POOCH.
0 · Reply
PrecisionSPYoptions
PrecisionSPYoptions Jul. 16 at 4:48 AM
$DTIL
0 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 6:40 PM
$DTIL wasted time and money with this garbage in this great bull market period
1 · Reply
Florestan
Florestan Jul. 14 at 1:33 PM
$DTIL azer-cel is looking like a blockbuster asset. Too bad we only have royalties for it if it ever gets out there. Good validation of ARCUS still.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Jul. 14 at 12:45 PM
$DTIL https://vir.com.vn/imugene-reports-strong-results-for-azer-cel-in-dlbcl-trial-132453.html
1 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 7:00 AM
$DTIL reiterating my target
1 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 6:57 AM
$DTIL $PRME Even relatively gene editing companies are highly valued than precision garbage. Big funds are not interested even when it's MC is less than $50M. So this is really a garbage company. There must be a valid reason why Eli Lilly walked out the partnership with Precision biosciences.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Jul. 13 at 9:54 PM
$DTIL hmmm..... https://www.afr.com/street-talk/imugene-preps-to-dazzle-market-with-new-clinical-data-cash-call-20250713-p5mej1
1 · Reply
pinkal
pinkal Jul. 13 at 8:19 PM
$DTIL sold out, sense 3s and 2s here in the short run, may nibble and come back after next pr, till then, this may just drift lower slow and steady
0 · Reply
Rybod30
Rybod30 Jul. 11 at 3:17 PM
$DTIL $5 resistance, gonna be a tall ask without positive PR…
0 · Reply
Latest News on DTIL
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jun 25, 2025, 7:01 AM EDT - 20 days ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 14, 2025, 4:30 PM EDT - 2 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 8, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 7, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2025, 7:00 AM EDT - 2 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 15, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 21, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 20, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 19, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 17, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Mar 12, 2025, 8:00 AM EDT - 4 months ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 24, 2025, 7:01 AM EST - 5 months ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 2:27 PM EST - 5 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Feb 19, 2025, 7:01 AM EST - 5 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 29, 2025, 7:01 AM EST - 5 months ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 10, 2025, 2:18 PM EST - 6 months ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 10:01 AM EST - 6 months ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 6 months ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Dec 18, 2024, 7:01 AM EST - 7 months ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 21, 2024, 7:01 AM EST - 8 months ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 15, 2024, 7:00 AM EST - 8 months ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 7:01 AM EST - 9 months ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 29, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 28, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 4:15 PM EDT - 9 months ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Oct 24, 2024, 8:47 AM EDT - 9 months ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Oct 21, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Oct 16, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 3, 2024, 7:01 AM EDT - 10 months ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Sep 30, 2024, 7:01 AM EDT - 10 months ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Sep 12, 2024, 7:15 AM EDT - 10 months ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Sep 4, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Sep 3, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:15 AM EDT - 1 year ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Participate in Upcoming August Investor Conferences

Jul 31, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Jul 29, 2024, 4:15 PM EDT - 1 year ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Jul 8, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Jul 1, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Jun 27, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.

Jun 20, 2024, 7:00 AM EDT - 1 year ago

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Jun 5, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Precision BioSciences to Participate in Upcoming June Investor Conferences

May 30, 2024, 7:00 AM EDT - 1 year ago

Precision BioSciences to Participate in Upcoming June Investor Conferences

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 7:00 AM EDT - 1 year ago

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 8, 2024, 8:15 AM EDT - 1 year ago

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 7, 2024, 4:30 PM EDT - 1 year ago

Precision BioSciences to Report First Quarter Results on May 13, 2024

Impatient_Investor
Impatient_Investor Jul. 16 at 6:01 AM
$DTIL DTIL's partner shareholding below. See the institutional shareholding. Retailers always chase garbage stocks because they are being manipulated and trapped by paid pumpers like POOCH.
0 · Reply
PrecisionSPYoptions
PrecisionSPYoptions Jul. 16 at 4:48 AM
$DTIL
0 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 6:40 PM
$DTIL wasted time and money with this garbage in this great bull market period
1 · Reply
Florestan
Florestan Jul. 14 at 1:33 PM
$DTIL azer-cel is looking like a blockbuster asset. Too bad we only have royalties for it if it ever gets out there. Good validation of ARCUS still.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Jul. 14 at 12:45 PM
$DTIL https://vir.com.vn/imugene-reports-strong-results-for-azer-cel-in-dlbcl-trial-132453.html
1 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 7:00 AM
$DTIL reiterating my target
1 · Reply
Impatient_Investor
Impatient_Investor Jul. 14 at 6:57 AM
$DTIL $PRME Even relatively gene editing companies are highly valued than precision garbage. Big funds are not interested even when it's MC is less than $50M. So this is really a garbage company. There must be a valid reason why Eli Lilly walked out the partnership with Precision biosciences.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Jul. 13 at 9:54 PM
$DTIL hmmm..... https://www.afr.com/street-talk/imugene-preps-to-dazzle-market-with-new-clinical-data-cash-call-20250713-p5mej1
1 · Reply
pinkal
pinkal Jul. 13 at 8:19 PM
$DTIL sold out, sense 3s and 2s here in the short run, may nibble and come back after next pr, till then, this may just drift lower slow and steady
0 · Reply
Rybod30
Rybod30 Jul. 11 at 3:17 PM
$DTIL $5 resistance, gonna be a tall ask without positive PR…
0 · Reply
Impatient_Investor
Impatient_Investor Jul. 11 at 7:14 AM
$DTIL one more thing Prime Medicine was started in 2019 but precision garbage was founded in 2006. Prime is going to be acquired.
0 · Reply
Impatient_Investor
Impatient_Investor Jul. 11 at 7:11 AM
$DTIL $PRME silently went up 400% in the last three months. Have you seen anything related to this in any forums or price targets news from analysts? You wont because they give targets for garbage companies to divert retail attention so institutional investors can load the real buyout or good biotech companies at cheaper price.
1 · Reply
pinkal
pinkal Jul. 10 at 6:34 PM
$DTIL dumper another 10k shs at 4.8, left with 10k shs, average with profit now below 4.
0 · Reply
Berakhot
Berakhot Jul. 10 at 4:26 PM
$DTIL been a good swing off low 4s :)
0 · Reply
aw20
aw20 Jul. 9 at 10:09 PM
$DTIL still holding. road to +5 👀
0 · Reply
Pitoentuboca
Pitoentuboca Jul. 9 at 6:54 PM
$DTIL IM OUT LETS BUY THE DIP $$$$$$$ 4.50 IM WAITING 1 TRILLION BILLION SHARES $$$$$
1 · Reply
Wyckoff_G
Wyckoff_G Jul. 8 at 6:29 PM
$DTIL im going to tell you guys a little secret, this is almost done with accumulation 😉. Im waiting for confirmation at over $5 and i will join you. I think you guys will be happy in August. See you soon! 👀
0 · Reply
Florestan
Florestan Jul. 8 at 6:25 PM
$DTIL still trailing the boom in CRISPR names, I guess we need that HBV results.
0 · Reply
Pitoentuboca
Pitoentuboca Jul. 8 at 2:37 PM
$DTIL looking good 1 last dip $420 smoke break $$$$$ wehre my pillsssss $$$$
1 · Reply
Pitoentuboca
Pitoentuboca Jul. 7 at 3:48 PM
$DTIL TIME TO RISE $4.48 $$$$$$$ GET READY $$$$$
0 · Reply
Pitoentuboca
Pitoentuboca Jul. 3 at 3:17 PM
$DTIL when the haters come out you know its time to buy impatient investor jajajaaja are
0 · Reply
Impatient_Investor
Impatient_Investor Jul. 3 at 9:45 AM
$DTIL what these two guys have fone to earn millions as salary, particularly the CFO. Daylight robbers.
0 · Reply